SCHEMBL457126

SCHEMBL457126

O=C1C(=NNC(=S)Nc2ccccc2)Nc2ccc([N+](=O)[O-])cc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
MAPT P10636 5/20 0.51
HPGD P15428 3/20 0.51
GAA P10253 2/20 0.51
CAPN9 O14815 1/20 0.47
CASP3 P42574 1/20 0.47
SMN1; SMN2 Q16637 5/20 0.46
HTT P42858 3/20 0.46
LMNA P02545 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
NPC1 O15118 2/20 0.46
ALOX12 P18054 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
POLB P06746 1/20 0.42
RAB9A P51151 1/20 0.42
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL457611 0.87 ALDH1A1 (0.47) ALDH1A1MAPTHPGDGAACAPN9
SCHEMBL455700 0.87 ALDH1A1 (0.47) ALDH1A1MAPTHPGDGAASMN1; SMN2
SCHEMBL455908 0.85 RRM1 (0.44) ALDH1A1MAPTHPGDGAACAPN9
SCHEMBL469856 0.85 ALDH1A1 (0.51) ALDH1A1MAPTHPGDGAACAPN9
SCHEMBL456020 0.81 LMNA (0.51) ALDH1A1MAPTCAPN9CASP3SMN1; SMN2
SCHEMBL469858 0.78 CA1 (0.54) ALDH1A1MAPTHPGDGAACAPN9
SCHEMBL454941 0.75 ALDH1A1 (0.46) ALDH1A1MAPTGAASMN1; SMN2LMNA
SCHEMBL18955695 0.74 CA2 (0.62) ALDH1A1MAPTGAACAPN9CASP3
SCHEMBL469874 0.74 TTR (0.57) ALDH1A1MAPTGAASMN1; SMN2HTT
SCHEMBL31492004 0.74 KMT2A (0.56) ALDH1A1MAPTHPGDSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
EP-2240175-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) 2010-10-20 EP disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed